Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
Protocol ID
J10-MC-JZHD
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapsed/ refractory
Location
NSW, WA
Sponsor
Eli Lilly and Company
Collaborators
New Approaches to Neuroblastoma Therapy Consortium (NANT)
Innovative Therapies for Children with Cancer in Europe (ITCC)
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 years to 21 years
International registry ID's
NCT04106219
Back to Registry
Study Title A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma
Protocol ID J10-MC-JZHD
Disease (Sub Disease) Solid tumours
Diagnosis Stage Relapsed/ refractory
Location NSW / WA
Sponsor Eli Lilly and Company
Collaborators New Approaches to Neuroblastoma Therapy Consortium (NANT)/ Innovative Therapies for Children with Cancer in Europe (ITCC)
Links https://clinicaltrials.gov/ct2/show/NCT04106219
Trial Status Open
Trial Open Date 11/06/2020
Sites The Children's Hospital at Westmead / Perth Children's Hospital
Study Type Treatment
Phase Phase 1
Age Eligibility 2 years to 21 years
International registry ID's NCT04106219